14 March 2017 - The Department of Health has asked the NICE to produce guidance on the use of nivolumab in the NHS in England by patients with relapsed or refractory classical Hodgkin lymphoma.

The Appraisal Committee is minded not to recommend nivolumab, within its marketing authorisation, as an option for treating relapsed or refractory classical Hodgkin lymphoma.

The committee recommends that NICE requests from the company for the second appraisal committee meeting revised probabilistic cost- effectiveness analyses comparing nivolumab with standard of care, which incorporate the committee’s preferred assumptions regarding method of indirect comparison, costs and utilities. The analyses should also explore the use of UK data for standard of care (for example, from the Haematological Malignancy Research Network) and a range of subsequent allogeneic stem cell transplant rates for both nivolumab and standard of care that are higher than those used in the Cheah and Perrot studies and are from UK data.

The use of nivolumab on the NHS will be considered at a second appraisal committee meeting on 12 April 2017.

Read NICE Appraisal Consultation Document for nivolumab